![Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-5021600-150x150.jpg "Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37] 24")
DEA Moves to Schedule Four Emerging Synthetic Opioids
The Brorphine Schedule I process is moving forward as DEA targets four emerging synthetic opioids for temporary federal control. The drugs are appearing in illicit drug seizures and toxicology testing, including fatal cases involving cychlorphine. The…
Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA has placed MDMB-4en-PINACA in Schedule I due to its high abuse potential and lack of accepted medical use. This synthetic cannabinoid poses significant health risks including seizures and psychosis. Awareness of MDMB-4en-PINACA Schedule I status…
Policy Watch: 17 Regulatory Updates — March 14, 2026
This update covers federal cannabis regulatory updates relevant to clinicians and patients. Key DEA scheduling actions affect synthetic cannabinoids and controlled substances. Understanding these federal cannabis regulatory updates is essential for…
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
The scheduling of novel synthetic opioids such as butonitazene, flunitazene, and metodesnitazene in Schedule I highlights their high abuse potential. This regulatory update aids clinicians in recognizing these substances with no accepted medical use.…
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
The schedules of controlled substances placement by the DEA now include etodesnitazene, N-pyrrolidino etonitazene, and protonitazene in Schedule I. These synthetic opioid analogs have high abuse potential and no accepted medical use. Clinicians should be…
Policy Watch: 20 Regulatory Updates — March 10, 2026
This update covers DEA scheduling synthetic opioids and regulatory changes relevant to cannabis clinicians. The rescheduling of marijuana signals potential federal recognition of cannabis medical utility. These regulatory updates impact clinical practice…